Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg Ulcers

NCT01552447 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to determine whether the EpiFix human amniotic membrane is effective in the treatment of venous leg ulcers.

Conditions Studied

Interventions

  • OTHER EpiFix
  • OTHER Compression Therapy

Study Locations (5)

Pennsylvania

  • St. Vincent's Health Center — Erie
  • Armstrong County Memorial Hospital — Kittanning

Florida

  • Eric J. Lullove DPM — Boca Raton

Massachusetts

  • MetroWest Medical Center — Framingham

Oklahoma

  • St. Johns Wound Center — Tulsa

Trial Details

FieldValue
Enrollment Target 98 participants
Start Date 2012-03
Est. Completion 2014-05
Phase NA

Sponsor

MiMedx Group

9 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01552447

The ClinicalTrials.gov registry entry for NCT01552447 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MiMedx Group, which has 9 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Venous Leg Ulcer appearing as the primary indexed condition, and to 2 interventions — of which EpiFix is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01552447 reports 5 study locations spanning 4 distinct geographic areas — top geographies include Pennsylvania, Florida, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01552447 about?

NCT01552447 is a clinical study titled "Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg Ulcers". The purpose of this study is to determine whether the EpiFix human amniotic membrane is effective in the treatment of venous leg ulcers.

What is the current status of trial NCT01552447?

This trial is currently completed. It is a NA study. The enrollment target is 98 participants. The study started on 2012-03. Estimated completion is 2014-05.

What conditions does trial NCT01552447 study?

This clinical trial studies the following conditions: Venous Leg Ulcer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01552447?

The interventions under investigation include: EpiFix (OTHER), Compression Therapy (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01552447?

This trial is sponsored by MiMedx Group, which has 9 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01552447 being conducted?

This trial has 5 study locations across Florida, Massachusetts, Oklahoma, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial